|Podcasts|July 6, 2020

Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC

In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C

ByJoy Maulik, CRNP,Susanne A. Quallich, PhD, ANP-BC, NP-C, CUNP, CMHE, FAUNA, FAANP

August 20th 2026

FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC

ByHannah Clarke

August 17th 2026

Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC

ByNima Almassi, MD

August 13th 2026

Pearls & Perspectives: Patient Expectations, Physician Autonomy, and Life Beyond Surgery, With Andrew T. Cohen, MD, FACS

ByAmy M. Pearlman, MD,Andrew T. Cohen, MD, FACS

August 12th 2026

Blue light cystoscopy is tied to higher resource use, not health care cost, in NMIBC

ByHannah Clarke

August 11th 2026

Latest CME

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Related Content

The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C

FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC

Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC

Pearls & Perspectives: Patient Expectations, Physician Autonomy, and Life Beyond Surgery, With Andrew T. Cohen, MD, FACS

Blue light cystoscopy is tied to higher resource use, not health care cost, in NMIBC

Latest CME

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Trending on Urology Times

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC